La Jolla Pharmaceutical Company – Consensus Indicates Potential 138.7% Upside

Broker Ratings

La Jolla Pharmaceutical Company found using ticker (LJPC) have now 3 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 20 and 4 with a mean TP of 10.67. Now with the previous closing price of 4.47 this would imply there is a potential upside of 138.7%. The day 50 moving average is 4.48 and the 200 day moving average is 4.33. The company has a market cap of $120m. Find out more information at: http://lajollapharmaceutical.com

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company offers GIAPREZA (angiotensin II), a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. It is also developing LJPC-0118 for the treatment of severe malaria; and LJPC-401 (synthetic human hepcidin), an investigational product to treat conditions characterized by iron overload. The company was founded in 1989 and is headquartered in San Diego, California.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index